The role of PAF and its antagonism in transplantation: Organ ischemia and preservation by Ontell, SJ et al.
22 
The Role of PAF and Its Antagonism 
in Transplantation: Organ Ischemia and 
Preservation 
Sheryl J. Onte" 
Case Western Reserve University School of Medicine, Cleveland, Ohio 
Leonard Makowka 
Cedars-Sinai Medical Center, Los Angeles, California 
Patrizia Boccagni 
University of Padua, Padua, Italy 
Thomas E. Surzl 
University of Pittsburgh School of Medicine and Veterans Administration 
Medical Center, Pittsburgh, Pennsylvania 
INTRODUCTION 
Human beings have long dreamed of substituting a healthy organ for one no 
longer capable of functioning, but it is only recently that they have been able to 
solve some of the technological problems that would permit usccessful organ 
transplantation. Successful organ transplantation has required the development 
of new surgical techniques. particularly the improvement of vascular 
anastomoses. It has also necessitated the development of immunosuppressive 
methods to prevent allograft rejection. Finally it has stimulated the investigation 
of new methods of organ preservation to improve organ sharing and procurement 
over long distances and to maximize optimal donor-reCipient matching. 
Although the techniques necessary for vascular anastomoses were developed 
more than 60 years ago by Carrel (1). it was not until 1951 that Lawer and 
Dubost performed the ftrst clinical renal transplant (2)_ By 1963 Starzl et al. 
performed the rust human liver transplant (3), and in 1966 Lillehei et aI. 
performed a pancreas transplant (4).ln 1967, clinical small bowel transplanta-
tion had been attempted as well (5). With the development of extracorporeal 
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circulation in 1960 by lower and Shumway, cardiac transplantation became a 
possibility, and the flIst cardiac transplant was performed in 1967 by Barnard 
(6,7). 
A better understanding of the process of organ rejection and improved donor_ 
recipient matching have decreased chances of allograft rejection after trans-
plantation. Early methods of immunosuppression included thoracic duct 
drainage and total body irradiation (8). These were soon replaced by the 
phannacological agents azathioprine and antilymphocyte globulin (9,10). The 
introduction of cyclosporin has greatly improved survival rates for cardiac and 
liver transplant recipients (11). Although the ideal treatment for rejection has 
yet to be found, great strides have been made, thus rendering transplantation a 
viable answer to the patient with a failing organ. 
The limited number of organs available for transplantation often necessitates 
the transportation of organs over great distances. Although all current attempts 
at organ preservation use some degree of hypothermia, at present there are no 
consistently successful long-term methods for ensuring organ viability. Maximum 
acceptable cold storage times in the clinical situation for kidney, heart, and liver 
are 48-72,4-6, and 8-10 h. respectively (12-14). 
ISCHEMIA AND REPERFUSION IN) URY 
Techniques currently used for liver preservation have been borrowed and 
modified from those used for renal preservation. Since these methods involve 
some degree of hypothermia, the effects of hypothermia as well as those of 
ischemia must therefore be addressed. Ischemic injury results in morphological 
changes in cellular membranes and in mitochondria (15). Aerobic metabolism 
ceases, ATP is depleted, and metabolic products accumulate (16). Eventually all 
energy-requiring cell functions are terminated. Inactivation of the sodium pump 
secondary to A TP depletion results in cell swelling due to the passive exchange 
of ions and water (17,18). Of key importance is determining at what point 
ischemic injury becomes irreversible. A TP levels in ischemic organs drop precipi-
tously, reaching very low levels long before the tissue is unable to recover 
(19-23). The loss of total intracellular adenine nucleotides is somewhat more of 
a prognostic factor (21,22,24,25). Dysfunction of cellular membranes is charac-
teristic of irreversible ischemic injury (26,27). Cellular injury follOWing ischemia 
may occur during the reperfusion period rather than during the period of 
ischemia (28). Implicated in this reperfusion injury are calcium ion fluxes and 
damage mediated by oxygen free radicals (28-32). 
Studies by Farber et al. relate the irreversibility of ischemic injury to the 
inability to restore mitochondrial function and evidence of plasma membrane 
damage (28). The mitochondrial abnormalities are related to changes in Iong-
chain acyl-CoA metabolism, with inhibition of adenine nucleotide translocation 
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and potentiation of calcium-dependent increase in permeability in the inner 
mitochondrial membrane. Disorders in phospholipid metabolism are probably 
the critical lesions producing irreversible cell injury. The mechanism is thought 
to be the activation of endogenous phospholipases by increased cytosolic free 
calcium. 
The interruption of the blood supply to the rat liver produces a progressive 
loss of phospholipids from the ischemic cells. Microsomes from lipid-depleted 
postmitochondrial supernatants have alterations in structure and function with 
inhibition of glucose-6-phosphatase and calcium pump activities and 25- to 
50-fold increases in passive permeability to calcium (27). EM studies of freeze-
fractured micro somes reveal fewer intramembranous particles, bare membrane 
regions devoid of particles, and areas containing aggregates of intramembranous 
particles (27). 
Microvascular abnormalities have been documented in myocardial reperfusion 
injury (33). Localized endothelial swelling, "blebs," increased capillary perme-
ability, plugging of the microvasculature with polymorphonuclear leukocytes, 
and microscopic zones of hemorrhage have all been demonstrated (33). 
ORGAN PRESERVATION FOR TRANSPLANTATION 
Hypothermia reduces metabolism and, therefore, would appear to be a simple 
method to minimize ischemic changes. Unfortunately, decreases in temperature 
do not affect all processes uniformly, and cooling itself may be damaging (34). 
Nonetheless. all currently used liver preservation protocols, including hypo-
thermic storage, hypothermic pUlsatile perfusion, hypothermic hyperbaric 
oxygenation. intermittent hypothermic perfusion, and freeZing, involve 
hypothermia. 
Hypothermic storage remains the technique used in clinical liver transplanta-
tion today. In 1960, Starzl et a1. experimentally transplanted livers stored at 4°C 
in heparinized Ringer's lactate for up :0 120 min (35). Since that time, modifica-
tions in storage solutions have extended the period of hypothermic ischemic 
storage that allow organ viability. Using an electrolyte-dextran solution, human 
livers were preserved for 2-3 h and up to 5 h (36-38). Flush perfusion with 
plasma protein fraction and hypothermic storage in ice has given reliable 4 h 
preservation of the human liver (39). Lambotte et al. were able to successfully 
preserve canine livers for ISh using Collin's C-2 solution with isoproterenol 
(40). Schalm et al. carried out a controlled study evaluating fow different 
preservation fluids with marked differences in ionic composition. pH, and 
osmolarity in pigs and dogs and found no significant difference with preserva-
tion up to 6 h (41). Benichou et al. found that after 18 h plasma and Collin's 
SOlUtions permitted survival, whereas lactated Ringer's did not (42). Toledo-
Pereyra et al. successfully preserved canine livers for 24 h utilizing hyperosmolar 
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colloid or crystalloid solutions (43). Monden and Fortner have used modified 
Sack's solution and prostacyclin to successfully preserve canine livers for 24 and 
48 h (44). Recently, Jamieson et al. have reported success with 24-30 h 
preservation of the canine liver utilizing static hypothermic storage in a unique 
preservation solution developed at the University of Wisconsin (45). 
Extended preservation has been obtained with hypothermic pulsatile perfu-
sion: however, its complexity and expense currently preclude its use in clinicaJ 
liver transplantation. Using a mixture of Eagle's and Hank's media, Slapak et ai. 
preserved canine livers by perfusion for a period of 6 h (46). Turner and Alican 
reported greater than 50% survival for more than 4 days for livers perfused for 
20 h with homologous serum and low pH (47). Preservation of the canine liver 
for 24 and 48 h using pulsatile hypothermic perfusion, membrane oxygenation. 
and cryoprecipitated plasma perfusate has been reported (48,49). Using the 
model of lluxiliary liver allotransplantation. Toledo-Pereyra has shown that a 
modified silica gel fraction with allopurinol and methylprednisolone improves 
graft survival and function after 24 h hypoth.ermic pulsatile perfusion (50). In 
the rat liver, Fuller et aI. obtained good preservation of metabolic activity by 
perfusion with a synthetic solution containing gelatin polypeptides (51). 
Furthermore, attempts to prevent or diminish ischemic injury associated with 
organ procurement and preservation have involved the utilization of several 
pharmacological agents. Prostacyclin has been used to enhance survival of canine 
livers preserved by hypothermic storage, and it has been shown to improve the 
survival of ischemically damaged liver allografts (44,52,53). Chlorpromazine has 
been found to prevent much of the calcium-mediated injury seen upon reper-
fusion (28,54). There has been much interest recently in the role of oxygen free 
radicals in ischemia and reperfusion injury (30-32.55,56). Catalase, superoxide 
dismutase. and allopurinol have been shown to protect against reperfusion injury 
mediated by oxygen free radicals. Other antioxidants and calcium channel 
blockers have also been used in an attempt to ameliorate ischemia and 
reperfusion injury. Udoflazine, a calcium channel blocker, has been shown to 
protect against reperfusion injury during small bowel transplantation (57). 
a-Tocopherol has been demonstrated to prevent oxygen free radical damage in 
ischemic rat liver (58): Marubayashi et a1. also used coenzyme QIO (ubiquinone) 
to prevent ischemic hepatocyte damage, presumably by protection of 
membranes from lipid peroxidation, with preservation of calcium homeostasis 
and restoration of mitochondrial functions (59). 
Platelet-activating factor (PAF) is a key inflammatory mediator elaborated by 
a variety of cell types, including platelets, neutrophils. and the endothelium. and 
is intimately involved in the microcirculatory response to both non immunologic 
and immunologic inflammatory stimuli (60-65). Many of the pathophysiological 
responses and the microcirculatory failure that result from PAF release mimic 
the progression of responses observed after ischemia and reperfusion injury. 
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SOZ 63-441 (Sandoz Company) is a potent receptor antagonist of PAF, which 
can inhibit all known biologic responses to PAF (65). Thus, the availability of 
such an antagonist could give further insight into the basic mechanisms involved 
in the ischemic process and could have significant potential as a therapeutic 
agent for both warm and cold ischemic organ injury. 
THE ROLE OF PAF AND ITS ANTAGONISM IN 
INFLAMMATION AND INJURY TO 
THE MICROCIRCULATION 
PAF is unequaled by any other single autacoid in its potential for being released 
and for mediating virtually every aspect of acute, basic allergic, and inflamma-
tory reactions (65). In addition to its effects on platelets, platelet-activating 
factor induces neutrophil aggregation and activation and superoxide anion 
release and acts directly on vascular endothelium to increase permeability (66). 
The most prominent and species-constant effect of PAF is increased vascular 
permeability (67,68). PAF alters the molecular organization of cytoskeletal 
proteins that control endothelial permeability (69). Human endothelial cells 
stimulated by P AF retract and lose reciprocal contact. Stress fibers disappear or 
become less regular, resulting in "bleb" formation (69). Bleb formation is also 
seen in ischemia and reperfusion injury (70). In addition to the direct effect of 
PAF on the endothelium, it indirectly elicits endothelial damage by amplifying 
leukocyte responses (71). 
The mediators and cascades involved in the inflammatory response associated 
with ischemia and reperfusion are quite complex and integrally interrelated and 
probably represent a nonspecific complicated process resulting in a failure of the 
microcirculation and organ injury. This interrelationship prompted our labora-
tory to investIgate the role of PAF, which had already been demonstrated to be 
a potent mediator in inflammation, and PAF antagonism, which we had already 
demonstrated could prevent a similar pathophysiological phenomenon of 
antibody-mediated injury to the endothelium and hyperacute rejection 
in ischemia and reperfusion injury. To further define the role of PAF in 
the microcirculatory injury seen following ischemia and reperfusion injury, we 
attempted to modify the injury resulting from both warm and cold ischemia 
with a potent PAF receptor antagonist, SDZ 63-441 (Sandoz Company), using 
the isolated perfused rat liver (IPRL) (72). Two sets of experiments were 
undertaken. The fust evaluated the effect of pretreatment with SDZ 63-441, 
• POtent PAF receptor antagonist, on hepatic function following 90 min of 
"ann ischemia. The second set of experiments utilized SDZ 63-441 pretreatment 
11\ COmbination with lJW-lactobionate solution (45) to enhance hepatic function 
fonowing 24 h of static hypothermic preservation. Liver function was evaluated 
USing the isolated perfused rat liver (71). 
424 Ootell et at. 
THE ISOLATED PERFUSED RAT LIVER 
The isolated perfused rat liver has proven to be a simple, inexpensive, and useful 
model for the study of liver function (73-78). The model lends itself to trans-
plantation research as it allows the evaluation and manipulation of the intact 
organ removed from the donor without requiring immediate transplantation into 
a recipient. Using the perfusion system, it is possible to maintain near· 
physiological cOl1tiitions and yet allow greater freedom in adjusting variables 
than in the intact animal. The model allows maintenance of the liver in a viable 
condition for variable periods of time, so that it can be transplanted into a 
recipient as a fmal test of the experimental conditions (74). 
The perfusion apparatus is a recirculating system that consists of a pulsatile 
pump, "Hamilton lung" oxygenator, debubbler and reservoir, effluent collecting 
basin, blood infusion mter, platelet trap, and in·line thennometer (78,79). 
The temperature in the enclosed system is maintained at 37°C by.a circulating 
water bath. The liver is perfused via the portal vein from a height of 18 cm, 
which is an appropriate rat portal vein pressure (80). The flow through the 
liver is determined by the resistance in the intrahepatic vasculature (15-20 
ml/min). The blood flow via the portal vein should be approximately 1.25 
ml/min per g liver and should not exceed a flow rate of 5 ml/min per g 
liver or significant barotrauma results (81). Oxygen extraction using the 
isolated perfused rat liver of the fasted liver has been reported to be 
greater than 1.0 Iill102 per min per g liver and in the fed liver is greater 
than 2.0 ~MO per min per g liver and increases fivefold with the 
addition of taurocholate to the perfusion medium (84). A 95% oxygen-
5% carbon dioxide mixture is used to maintain oxygenation (P02 = 
500 torr). 
The perfusate is a dilute blood solution prepared from 2 parts by volume 
heparinized fresh whole rat blood and I part Krebs bicarbonate buffer for a 
hematocrit of 25, which is adequate for maintenance of tissue oxygenation in 
this model, and pH 7.5 (85,86). 
The isolated perfused rat liver is an excellent screening model for pharmaco. 
logical agents that may be useful in the prevention of reduction of ischemia and 
reperfusion injury. 
THE PROTECTIVE EFFECT OF A PAF RECEPTOR 
ANTAGONIST (SDZ 63·441) ON POSTISCHEMIC 
HePATIC FUNCTION FOLLOWING 90 MIN OF 
WARM ISCHEMIA 
Our laboratory has evaluated the ability of SOZ 63-441, a potent PAF receptor 
antagonist (87), to prevent wann ischemic injury to the liver (88). 
f 
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Materials and Methods 
Male Lewis rats purchased from Charles River, weighing 225-300 g, were used as 
liver donors. and male Lewis rat retired breeders were used as blood donors in 
these experiments. Animals were acclimatized for 1 week prior to experimenta· 
tion and housed in a standard animal facility at the University of Pittsburgh. 
Animals were fed standard rat chow and water ad libitum. Guidelines for the 
care and use of laboratory animals of the University of Pittsburgh were followed. 
Inhalational anesthesia was induced and maintained with methoxyflurane. 
The abdomen was entered through a transverse incision. All animals received 
300 units of heparin IV 5 min prior to cannulation of the bile duct and induc· 
tion of total hepatic ischemia. Both the hepatic artery and portal vein were 
ligated. At the time of harvest the liver was flushed via the portal vein with 
60 ml cold (4°C) heparinized lactated Ringer's solution from a height of 20 cm 
immediately after venting the vena cava. The portal vein was cannulated using a 
blunted 18 gauge needle. After 90 min of total in situ ischemia, the liver was 
harvested and placed on the perfusion apparatus. 
Experimental groups were as follow: group I (control. no ischemia), the livers 
were immediately harvested (n = 7); group II, cannulation of the bile duct 
followed by induction of 90 min of total hepatic ischemia. after which the 
portal vein was cannulated and the livers harvested (n = 9); group III (no 
ischemia), rats received 20 mg/kg of SOZ 63·441 IV at the time of hepariniza. 
tion (n = 8); group IV. rats received 20 mg/kg of SOZ 63441 IV at the time of 
heparinization followed by induction of 90 min of ischemia (n = 9); group V, 
rats received 10 mg/kg of SOZ 63-441 IV at the time of heparinization followed 
by induction of 90 min of ischemia. All livers underwent 90 min of warm 
(37°C), oxygenated (p02 0& 500 torr), dilute sanguinous (Hct = 25; diluent, 
Krebs bicarbonate buffer, pH 7.4) perfusion (72). 
Baseline perfusate levels of SGOT and SGPT were measured using the 
Technicon RA 500 (Technicon) prior to placing the liver on the perfusion 
apparatus. Liver function during per{usion was determined by measuring bile 
production and SGOT and SGPT levels in the perfusate every 30 min. At the 
completion of the 90 min perfusion period, tissue was immediately freeze 
clamped in liquid nitrogen and A TP content was determined biochemically (89). 
Specimens were placed in formalin, embedded in paraffm, and cut and stained 
with hematoxylin and eosin (HSE) and PAS for light microscopy. An addi· 
tional three experiments were repeated per group for experimental groups I, II, 
and IV. and the livers were processed for electron microscopy. 
After 90 min of warm sanguinous perfusion the livers were perfused.fIXed via 
the portal vein with 20 m12.0% glutaraldehyde in 0.125 M cacodylate buffer at 
a rate of 5-10 ml/min, minced to 1 x 1 x I mm cubes, and placed in 2.0% 
glutaraldehyde for 2 h (89). The livers were postflXed in buffered 2.0% osmium 
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tetroxide, dehydrated in ethanol, and embedded in Epon-812. Blocks were CUt 
using a Reichert microtome. Semithin sections were stained with toluidine blue 
for light microscopy. Ultrathin sections were collected on grids, stained with 
uranyl acetate and lead citrate, and observed using a Phillips 300 electron 
microscope (90,91). 
All values were corrected to baseline by subtracting the values obtained prior 
to placing the liver on the perfusion apparatus from the subsequent measure· 
ments at 30,60, and 90 min of perfusion. The statistical evaluation was Carried 
out using an analysis of variance. When indicated, the Student's t·test was 
performed using the variances generated by analysis of variance (ANOVA) 
method (92). All values reported are expressed as a mean ± the standard error of 
the mean (SEM). P values of less than 0.05 were considered statistically 
significant. 
Results 
There was a significant increase in bile production (p < 0.(05) by those livers 
harvested from rats that were pretreated with 20 mg/kg IV of SDl 63-441 
(Table 1). Perfusate transaminase levels were Significantly lower than in the 
ischemic livers of animals pretreated with 20 mg/kg SDZ 63441 (p < 0.00 I. 
Table 2). There was no significant difference in transaminase release by 
SOZ 63441-treated and untreated livers from animals that underwent no 
ischemic injury. A TP levels were significantly higher in the ischemic livers pre· 
treated with 20 mg/kg of SOl 63441 compared with untreated livers (p < 0.05. 
Table 3). Ischemic livers from rats that were pretreated with only 10 mg/kg IV 
of SOl 63441 did not demonstrate improvement when compared to untreated 
livers in terms of bile production, transaminase release, or A TP content (Tables 
1 through 3). There was a significant difference in bile production, transaminase 
release, and A TP levels in untreated livers when comparing the group that did 
not undergo an ischemic period (Tables I through 3, p < 0.(01). 
All samples for electron microscopy were taken following the 90 min 
perfusion period. EM was done only for groups I, II, and IV. Electron micro-
scopy of the nonischemic control livers (group I) revealed intact, healthy. 
appearing hepatocytes as weU as intact well·preserved sinusoidal endothelial cells 
(Fig. 1 AI. The ischemic livers (group II) exhibited a patchy picture of hepato. 
ceUular damage (Fig. IB). Vacuolated and pale.staining nonviable helpatocytes 
containing many disrupted mitochondria were found interspersed with viable 
hepatocytes. The sinusoidal endothelium remained intact when covering viable 
hepatocytes but was disrupted in areas adjacent to nonviable hepatocytes 
(Fig. 2). Sections from ischemic livers that were harvested from donors pre· 
treated with SOl 63-441 (10 mg/kg, group IV) demonstrated relatively normal· 
appearing hepatocytes with few vaclk>les and intact sinusoidal endothelium 
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Table 1 Effect of SDZ 63441 Pretreatment on Bile Production 
Bile production (J.Il/min per g liver) 
Group 30 60 90 
1: 90 min 1.42 ± 0.15 1.80 ± 0.21 lo80±0.18 
perfusion only 
11: 90 min 1.83 ± 0.30 2.24 ± 0.28 2.29 ± 0.25 
perfusion + 
SDZ 63441 
(20 mg/kg) 
Ill: 90 min 0.003 ± 0.003 0.09 ± 0.03 0.15 ± 0.04 
ischemia + 
90 min perfusiona 
IV: 90 min 0.37 ± 0.07 0.49 ± 0.06 0.61 ± 0.05 
ischemia + 
90 min perfusion + 
SDZ 63-441 
(20 mg/kg)3 
V: 90 min ischemia + 0.06 ± 0.06 0.04 ± 0.04 0.02 ± 0.02 
90 min perfusion + 
SDZ 63441 
(10 mg/kg)a 
aBile production by Ischemic liver was essentially nil. Low-dose SDZ 63-441 00 mg/kg) did 
not result in an increase in bile production. SDZ 63-441-pretreated (20 mg!kg) livers 
produced si!!niftcantly more bile (p < 0.005) than untreated ischemic livers. 
(Fig. I C'). The patchy distribution of injury combined with the small cross-
sectional area observed with electron microscopy introduces the possibility that 
the sections viewed were not representative of the true morphological picture. 
In fact. sections of the ischemic nontreated livers could be found that mani-
fested relatively healthy appearing hepatocytes. To obtain a better overview, 
parafflll-embedded tissue was cut artd stained with H&£ and PAS for light 
microscopy. 
The nonischemic control livers exhibited normal healthy-appearing hepato-
cytes (Fig. 3A). PAS-stained sections were glycogen laden (not shown). The 
ischemic livers contained large patches of pale-staining, nonviable hepatocytes 
and vacuolization interspersed with normal-appearing hepatocytes (Fig. 38). 
PAS staining revealed large patchy areas of glycogen depletion (not shown). 
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Table 3 Effect of SDZ 63-441 Pretreatment on A TP Content 
Group 
1: 90 min perfusion onlya 
II: 90 min perfusion + SDZ 63-441 
(20 mg!kg) 
Ill: 90 min ischemia + 90 min perfusiona,b 
IV: 90 min ischemia + 90 min perfusionb + SDZ 63-441 
(20 mgikg) 
V: 90 min ischemia + 90 min perfusion + SDZ 63-441 
(10 mg/kg) 
429 
A TP (j..lmol/g liver) 
2.13 ± 0.11 
1.74 ± 0.11 
1.24 ± 0.11 
1.54 ± 0.08 
1.09 ± 0.12 
alschemic livers manifested a significant reduction in A TP content when compared with 
nonischemic livers tp < 0.00 I ). 
bThe liver tissue A TP content was significantly higher in group IV compared with group III 
(p < 0.05). 
Ischemic livers from donors pretreated with SOZ 63441 (20 mg/kg) also con-
tained some foci of pale-staining, nonviable hepatocytes and vacuolization 
(Fig. 3C). Although quantitative analysis was not carried out, the foci of injury 
in the SOZ 63-441-pretreated ischemic livers were generally smaller in size and 
less abundant than in the untreated ischemic livers. The pretreated ischemic 
livers were largely glycogen depleted. in fact, to a greater extent than even the 
untreated ischemic livers (not shown). Nonischemic livers from rats pretreated 
with 20 mg/kg of SOZ 63-441 had normal.appearing hepatocytes but also 
demonstrated patchy glycogen depletion (not shown). 
Discussion 
ISChemia and reperfusion injury appear to be integrally tied to the inflammatory 
response, resulting in microcirculatory failure followed by necrosis and cell 
death. The pathways implicated as causative of the injury to the microcircula-
tion that occurs in this process are multiple and complex. These highly inter-
related and redundant cascades involved in the mediation of ischemia and 
reperfusion injury make it highly likely that effective pharmacological modula· 
tion of the injury, leading to prevention of both warm and cold ischemic injury 
and ultimately to prolongation of organ preservation, will depend upon a 
POlypharmaceutical approach. 
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Figure 1 Low-magnification electron micrographs (x 1700) stained with uranyl 
acetate and lead citrate. (A) Nonischemic control liver. Note intact endothelium 
(E) and normal-appearing hepatocytes (H). (B) Ischemic liver. Note nonviable 
hepatocytes (arrows) interspersed with vacuolated but viable hepatocytes (H) 
and relatively intact endothelium (E). (C) Ischemic liver from an animal 
pretreated with 20 mgjkg IV of SDZ 63-441. Note normal-appearing hepato-
cytes (H) in this section along with an intact endothelium (E). 
Platelet-activating factor has been proposed as a potential key inflammatory 
mediator of the microcirculatory failure that results following ischemic organ 
injury. Platelet.activating factor is released from a number of cells, including 
endothelial cells, platelets, and neutrophils, and plays a Significant role in almost 
every aspect of the basic inflammatory response (65). In addition to its effects 
on platelets, PAF induces neutrophil aggregation, activation, and superoxide 
anion release and acts directly on vascular endothelium to increase permeability. 
It also has smooth muscle contracting properties (61). SOZ 63-441 is one of 
the most potent platelet.activating factor receptor antagonists developed 
to date (87). 
A dose-dependent protective effect against warm ischemia and reperfusion 
injury was clearly demonstrated after donor pretreatment with SOZ 63441. Bile 
production, transaminase release, and A TP content all exhibited significant 
improvement when compared with untreated ischemic controls in those livers 
from rats pretreated with 20 mg/kg IV of SOZ 63-441. When a lower dose of 
10 mg/kg IV of SOA 63441 was administered, no significant improvement in 
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liver function was demonstrated for any parameter measured when compared to 
ischemic controls. These results substantiate the important role of platelet. 
activating factor in ischemic organ injury and. moreover, introduces a potential 
therapeutic approach to organ ischemia and preservation through the inhibition 
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Figure 2 High-magnification electron micrographs (x 9700) stained with uranyl 
acetate and lead citrate. (A) Ischemic liver. The endothelium (E) remains intact 
over the variable hepatocyte (H), which contains vacuoles (V) but is lifted off 
the nonviable hepatocyte (arrows). (B) Ischemic liver from an animal pretreated 
with 20 mg/kg IV of SDZ 63-441. Endothelium tEl remains intact over the 
viable hepatocyte (H). 
( 
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of P AF by specific receptor antagonism. It is clear from the results reported 
here that prevention of warm ischemic injury to the liver and improved hepatic 
function could be achieved by the administration of SDZ 63-441 as a pretreat. 
ment to liver donors. Since rat platelets are through to be unresponsive to 
platelet.activating factor (87), PAF·mediated ischemic liver injury may be 
neutrophil dependent or, alternatively, may be due to some other PAF·mediated 
pathway. The improved postischemic hepatic function demonstrated with 
SDZ 63-441 pretreatment has encouraging implications for liver preservation. 
Because the group of animals pretreated with SDZ 63-441 (20 mg/kg) 
exhibited the most marked improvement in postischemic hepatic function, 
electron microscopy was performed on these livers to ascertain any histological 
improvement in organ status. Ischemic pretreated livers (group IV) were 
compared to ischemic (group II) and nonischemic (group I) controls, which 
were processed in an identical fashion. 
The morphological appearance of the nonischemic control livers was that of 
normal liver without any evidence of hepatocellular or endothelial injury, 
indicating that changes in the experimental groups are not artifactual. The 
general pattern of injury observed in the ischemic livers and the ischemic livers 
harvested from donors pretreated with SDZ 63-441 (20 mg/kg) was almost 
identical in nature and consisted of patchy hepatocellular vacuolization and 
nonviable hepatocytes interspersed with viable cells. However. the degree of 
injury appeared less severe in the group pretreated with SDZ 63·441 (group IV); 
the foci of damage were smaller and less abundant than in the untreated 
ischemic group (group 11). The vacuolization observed is characteristic of 
hypoxic injury (93-95). 
The sinusoidal endothelium was relatively spared even in the most severely 
damaged warm ischemic livers. This is of singular importance since the primary 
abnormality seen in livers following cold ischemic or preservation injury is 
endothelial disruption (73). Sinusoidal endothelial injury is apparent in livers 
injured by cold ischemia while still manifesting normal hepatocellular architec· 
ture. Hepatocellular injury manifested by vacuolization does not ocCur until 
prolongation of cold ischemic injury well past the point at which endotheial 
injury becomes apparent (73). This difference in morphology following warm 
and cold ischemia has only recently been appreciated and lends further credence 
to the belief that warm and cold ischemia represent two different and distinct 
types of injury (73). Moreover, it should become possible to use these different 
and specific pathological changes as predictors of organ function. 
The glycogen depletion observed in those livers pretreated with SDZ 63-441 
(groupS III and IV) was at rust puzzling since it would be expected that the 
mOre "healthy." better functioning livers would retain their glycogen. However. 
in addition to its role in the inflammatory response. PAF has a potent agonist 
effect on the glycogenolytic system in the rat liver (96). It is possible that 
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Figure 3 Light micrographs stained with hematoxylin and eosin (x 500). 
(A) Nonischemic control liver with normal-appearing parenchyma. (B) Ischemic 
liver with a moderate degree of vacuolization: vacuoles (V). (C) Ischemic liver 
from a rat pretreated with 20 mg/kg IV of SDZ 63-441. Note much lesser degree 
of vacuolization than in B. 
SOl 63-441, the structurally similar PAF receptor antagonist, may have 
the same action as PAF itself on the glycogenolytic system activate 
glycogenolysis. 
Briefly, in summary, the platelet.activating factor antagonist SDl 63-441 
significantly reduced hepatic warm ischemic injury in a dose·dependent fashion. 
thereby substantiating the role of platelet·activating factor in ischemic organ 
injury and introducing a novel therapeutic approach. 
IMPROVED FUNCTION OF LIVERS COLO STORED IN 
UW·LACTOBIONATE SOLUTION FOR 24 H AFTER 
PRETREATMENT WITH A PAF RECEPTOR ANTAGONIST 
(SOl 63-441 ) 
After demonstrating the protective effect of the PAF receptor antagonist 
SOl 63441 on hepatic function following warm ischemic injury, we evaluated 
the role of PAF antagonism in livers subjected to a cold ischemic insult. which 
f 
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Figure 3 (Continued) 
is much more germane to organ preservation (97). This study incorporated the 
use of UW-Iactobionate solution, a new preservation solution initially developed 
for pancreas preservation but shown to be much more effective for liver preser-
vation than the standard Eurocollin's solution (63.93,98,99). 
436 OntelJ et iI. 
Materials and Methods 
Animals, operative techniques, evaluation of hepatic function, electron micro. 
scopy, and statistical analysis are as in an earlier section, with the following 
exceptions: heparinization occurred 5 min prior to cannulation of the bile duct, 
and portal vein and the livers did not undergo any period of warm ischemia. 
The vena cava was vented and the liver immediately flushed via the portal vein 
with 20 ml cooled (4°C) preservation solution from a height of 20 cm. The liver 
was excised during the flushing period, weighed, immersed in preservation 
solution, and stored at 4°C. Prior to placement on the perfusion apparatus, 
livers were tlushed with 8 mllactated Ringer's solution to removed the preserva. 
tion solution. Livers were placed on the perfusion apparatus for 90 min as 
described earlier. 
Experimental groups were as fonows: group I, controls, levers were tlushed 
with lactated Ringer's solution and immediately placed on the perfusion 
apparatus (n = 7); group II, livers were flushed and stored with UW solution for 
24 h (n = 5); and group III, animals were pretreated with 20 mg/kg IV of 
SDZ 63-441 5 min prior to harvesting the liver, and the livers were tlushed and 
stored with UW solution for 24 h (n = 6). After storage. all livers were placed on 
the perfusion apparatus for 90 min. 
Livers were weighed immediately after harvesting and after the preservation 
period to assess tissue edema. SGOT, SGPT, LDH, and glucose levels were 
measured in the perfusate prior to placing the liver on the perfusion apparatus 
and every 30 min during perfusion. Bile production was measured after 30, 60. 
and 90 min. After 90 min of warm sanguinous perfusion the livers were perfused 
fIxed processed for electron microscopy. 
Results 
There were no signillcant differences in the weights of livers stored in UW solu. 
tion for 24 h regardless of pretreatment with SDZ 63-441; that is, neither group 
gained weight during the preservation period (Table 4). SGOT, SGPT. LDH. and 
Table 4 % Change in Liver Weight During Storage 
Group % Change3 
I: no preservation 
II: 24 h preservationb -5.7±O.9 
III: 24 h preservation + SOZ 63441b -3.1 ± 1.4 
bThe addition of SOZ 63441 did not significantly alter weight 
change during the storage period. 
( 
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glucose levels in the perfusate are listed in Table 5. The 24 h, UW-stored, 
SOZ 63441-pretreated livers (group III) did not release significantly more 
SGOT than controls (group I) until after 90 min of perfusion (p < 0.05), and did 
not release significantly more SGPT than controls (group I) after 30, 60, and 90 
min of perfusion. Although there was a consistent trend of decreased 
transaminase release in the SOZ 63441 pretreated, 24 h UW·stored livers 
(group III) when compared to 24 h UW-stored livers alone (group II), these 
differences did not reach statistical significance. 
Both pretreated (group III) and untreated (group II) stored livers released 
significantly more LDH into the perfusate than controls (group I, p < O.oI), 
and there was no significant difference between LOH liberation between the two 
groups that underwent preservation (groups II and III). 
Perfusate glucose levels were not significantly different between any of the 
three groups. Bile production results are listed in Table 6. Bile production by 
both the pretreated stored livers (group III) and the untreated stored livers 
(group II) was significantly decreased when compared with nonstored controls 
(group I). Those livers harvested from animals that were pretreated with 
SDZ 63441 and stored produced significantly more bile than those livers that 
were stored but not pretreated (p < 0.05). 
Electron microscopy revealed moderate endothelial cell disruption in both 
groups (groups II and III) of stored livers (Fig. 4A and B). Controls (group I) 
exhibited a completely intact endothelium (Fig. 4C). The parenchyma of the 
Table S Effect of SOZ 63·441 Pretreatment on Perfusate SGOT, SGPT, LOH, 
and Glucose Levelsa 
Perfusion SGOT SGPT LOH Glucose 
Group time (min.) (lU/liter) (IU/liter) (IU/liter) (mg/dl) 
No preservation 30 8±8 913 63 ± 53 114 ± 11 
60 24111 9±6 67170 115 ± 22 
90 34113 II ± 5 144173 112 ± 25 
24 h Preservation 30 73 ± 10 43 ± 7 5861105 269 ± 28 
60 128119 59 ± 11 8261 144 221 ± 25 
90 58 ± IS 681 11 902 ± 115 176123 
24 h Preservation 30 52 ± 9 9 ± 18 429 ± 62 209 ± 38 
+ SOZ 63-441 60 86 ± 16 20120 665162 166 ± 29 
90 109 ± 21 20 ± 19 832153 139122 
aThere was a consistent trend of decreased transaminase, LDH. and glucose release into the 
perfusate by group III livers when compared with group II, although this did not reach 
statistical significance. 
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Table 6 Effect of SOZ 63-441 Pretteatment on Bile Production 
Group 
I: no preservation 
II: 24 h preservationa 
III: 24 h preservation + SOZ 63-441 a 
Perfusion time 
(min.) 
30 
60 
90 
30 
60 
90 
30 
60 
90 
Bile productio; 
(pI/min per g liver) 
1.42±0.15 
1.80 ± 0.21 
1.80 ± 0.18 
0.58 ± 0.08 
1.08 ± 0.11 
1.14 ± 0.12 
0.87 ± 0.16 
1.31 ± 0.25 
1.51 ± 0.20 
aGroup III livers produced significantly more bile than group II livers (p < 0.05). 
Figure 4 High-magnification electron micrographs (x 9700) stained with uranyl 
acetate and lead citrate. (A) Liver preserved at 4°e for 24 h in UW-lactobionate 
solution. Note focal area of endothelial disruption (arrow. and normal-appearing 
hepatocyte (H). (B) Liver preserved at 4°e for 24 h in UW·lactobionate solution 
from an animal pretreated with 20 mg/kg IV of SOZ 63-441. Foci of endothelial 
disruption (arrows) characteristic of cold ischemic injury are present. Hepato-
cytes (H) remain normal in appearance. (e) Nonpreserved control liver exhibit-
ing intact endothelium (E), n0rII¥l-appearing space of Oisse ~lrK and healthy 
hepatocyte (H). I 
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Figure 4 (Continued) 
two groups (group II and III) of preserved livers remained healthy in appearance 
(Fig. 4A and B). There was no distinct difference in the morphology of the 
pretreated group (group III) when compared to the untreated group (group II). 
Of particular interest is that the pattern of injury demonstrated following cold 
, : 
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ischemia primarily involves the endothelium, whereas in the same experimental 
model, warm ischemic injury is primarily parenchymal in nature. 
Discussion 
Those livers excised from animals pretreated with SDZ 63-441 and stored for 
24 h (group III) produced significantly more bile than those that were stored but 
from untreated animals (group II). Since postrevascularization bile production is 
considered one of the most important indicators of graft viability and function 
used in clinical transplantation, this represents a considerable improvement in 
hepatic synthetic function. Although the other parameters of liver function 
evaluated in this study did not reach statistical significance, a sustained general 
trend toward improvement was evident for all variables. This study suggests that 
pretreatment of donor animals with the PAF antagonist SDZ 63-441 also has a 
beneficial effect on the reduction of cold ischemic injury of the liver as we 
previously described for warm ischemic injury. 
SUMMARY 
Platelet.activating factor is a central mediator of the cell·to-cell interaction 
involved in response to a multitude of stimuli that incite an inflammatory 
response. Its role in transplantation and the use of PAF antagonists as a thera· 
peutic approach have implications in drug toxicity, antibody.mediated injury 
(hyperacute rejection), and ischemia and reperfusion injury. In this chapter we 
have reviewed data that provide evidence supporting the role of PAF as a 
mediator of the microcirculatory failure that follows ischemia and reperiusion 
injury in both warm ischemia and cold ischemia. The use of PAF antagonists 
could have important clinical applications in organ transplantation. 
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